Investors are paying attention to
Biogen Inc. (NASDAQ: BIIB), as the stock's recent uptick has offered some relief following a 31% drop in the past year.
Inspire Trust Co. N.A., Resona Asset Management Co. Ltd., Invesco Ltd., Charles Schwab Investment Management Inc., LPL Financial LLC, E Fund Management Co. Ltd., and AIA Group Ltd have purchased stock amounts ranging from 2,000 to 136,200 shares in the past year.
Leqembi, Biogen's Alzheimer's drug has pulled focus with UBS raising the price target for Biogen's stock amid its development. The company's positive Q2 report and the analysis displaying strong analyst optimism concerning Biogen's outlook are driving the stock up. Additionally, Biogen's Tau-Targeting Therapy
BIIB080 has received FDA Fast Track Designation for Alzheimer's treatment. This news, combined with the first patient dosed in phase 3 of the
EMPEROR study of Zorevunersen, a potential disease-treating drug for Dravet Syndrome led to a 2.71% surge in Biogen's stock.
Biogen BIIB News Analytics from Tue, 07 Jan 2025 08:00:00 GMT to Sat, 16 Aug 2025 16:14:09 GMT -
Rating 7
- Innovation -1
- Information 8
- Rumor 2
